Irene Jennifer Denning

Title: Celebrating The Innovations of Irene Jennifer Denning in Cancer Therapeutics

Introduction

Irene Jennifer Denning is a prominent inventor based in San Diego, California, who has made significant strides in the field of cancer therapeutics. Her innovative work focuses on the development of antibodies that target human c-Met, a protein often associated with various types of tumors.

Latest Patents

Denning holds a patent for "Anti-c-Met Antibodies." This invention relates to antibodies or antigen-binding fragments that specifically bind to the extracellular domain of human c-Met. The patent details various compositions and kits that utilize these antibodies, providing critical methods for detecting human c-Met. This technology plays a vital role in identifying patients with tumors that express or overexpress human c-Met, thereby enhancing their treatment response with anti-c-Met therapeutics.

Career Highlights

Irene is currently employed at Eli Lilly and Company, where she contributes to groundbreaking research aimed at improving cancer treatment methodologies. Her expertise and dedication to advancing medical science position her as a key figure in her field.

Collaborations

Throughout her career, Denning has collaborated with notable colleagues, including Gregory Beuerlein and Julian Davies. Their collective efforts and shared knowledge have undoubtedly fueled innovation and expanded the potential impact of their work on cancer therapies.

Conclusion

Irene Jennifer Denning's contributions to medical innovation underscore the importance of research in developing effective cancer treatments. Her patent on anti-c-Met antibodies not only exemplifies her ingenuity but also holds promise for significantly improving patient outcomes in oncology.